Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25753684 | 0.75 | POLB (0.46) | POLBLMNATP53GAAHTT | |
| SCHEMBL210366 | 0.71 | OPRD1 (0.42) | OPRD1KCNH2OPRM1KDM4EALDH1A1 | |
| SCHEMBL2733434 | 0.67 | CHRM2 (0.44) | OPRD1KCNH2OPRM1POLBKDM4E | |
| SCHEMBL14338849 | 0.66 | KCNH2 (0.49) | OPRD1KCNH2OPRM1LMNAKDM4E | |
| SCHEMBL26248858 | 0.65 | POLB (0.48) | POLBLMNATP53GAAHTT | |
| SCHEMBL31546371 | 0.64 | LTA4H (0.50) | OPRD1KCNH2OPRM1 | |
| SCHEMBL30874886 | 0.63 | VNN1 (0.43) | POLBLMNATP53GAAHTT | |
| SCHEMBL28289061 | 0.62 | OPRD1 (0.40) | OPRD1KCNH2OPRM1SRPK1 | |
| SCHEMBL27645924 | 0.62 | LTA4H (0.49) | OPRD1KCNH2OPRM1POLBALDH1A1 | |
| SCHEMBL2662022 | 0.61 | CHKA (0.47) | OPRD1KCNH2OPRM1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-4205741-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | CYP2E1, CYP11B1, CYP27A1 | OPRD1 2868/4885KCNH2 4089/4885OPRM1 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.